Find a clinical trial location
Enroll a patient or find out how to register your clinic as a trial site
First line of the email MUST contain the NCT # and Site #
Available 24/7
Explore Novel CELMoD Trials
Iberdomide phase 3 studies
Mezigdomide phase 3 studies
Find the right golcadomide clinical trial for your lymphoma patient
Confirm EligibilityCELMoD=cereblon E3 ligase modulator; D=Darzalex® (daratumumab); d=dexamethasone; IA=interim analysis; Iber=iberdomide; K=Kyprolis® (carfilzomib); mAb=monoclonal antibody; Mezi=mezigdomide; NDMM=newly diagnosed multiple myeloma; Pom=POMALYST® (pomalidomide); RRMM=relapsed/refractory multiple myeloma; SCT=stem cell transplant; V=Velcade® (bortezomib).
Reference: Lonial S, Quach H, Dimopoulos MA, et al. EXCALIBER-RRMM: a phase 3, two-stage study of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. Poster presented at: Annual Meeting of the American Society of Clinical Oncology (ASCO); June 2-6, 2023; Chicago, IL.